CTLA4 and cancer: These monoclonal antibodies reactivate T-cell response against cancer cells, by blocking either the lymphocyte inhibitory receptor CTLA4 or the interaction between T-cell receptor PD-1 with its ligands PDL-1 and PDL-2 at the surface of cancer cells.